Please choose an option:

Enter Patient Site Visit Healthcare Professional Site

You are about to visit a website that contains clinical information created specifically for healthcare professionals. If you are not a healthcare professional and would like to remain on the patient site, please click CANCEL.

Continue
Cancel
The UDENYCA® Single-Dose Prefilled Autoinjector

Reduce your risk of chemotherapy-related infection without the need to return to the doctor's office1

The UDENYCA® autoinjector allows you to receive treatment from the comfort of home1,2

Delivers medicine in less than 10 seconds*3

*Please refer to the Instructions for Use before administering UDENYCA®.

How do you use the UDENYCA® autoinjector?

You may be prescribed the UDENYCA® autoinjector for at-home use. If so, your healthcare team will show you or your caregiver how to administer your treatment.

Watch a video to learn about administering treatment with the UDENYCA® autoinjector

For complete administration instructions, please see the Instructions for Use.

Only adults can self-inject UDENYCA® with the prefilled autoinjector.

Is the UDENYCA® autoinjector right for you?

The UDENYCA® autoinjector provides post-chemotherapy immune support you can receive in your doctor's office or self-administer from the comfort of home.1

The UDENYCA® autoinjector may be right if you:

Live far away from your doctor's office or depend on a caregiver for a ride

Have concerns with wearing an on-body injector

Want discretion and privacy around your treatment

Prefer to self-administer on your own time, as directed by your healthcare provider

Need to take extra precaution with your immune system4

Be sure to wait at least 24 hours after chemotherapy before administering.

References: 1. UDENYCA® (pegfilgrastim-cbqv) Patient Information. Available from Coherus BioSciences, Inc.; 2023. 2. Udenyca® Prefilled Autoinjector Instructions for Use. Available from Coherus BioSciences, Inc.; 2023. 3. Data on file. Coherus BioSciences, Inc.; 2023. 4. American Cancer Society. Watching for and Preventing Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/preventing-infections-in-people-with-cancer.html. Accessed April 20, 2023.
SEE MORELESS down arrow

What is UDENYCA®?

UDENYCA® is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

IMPORTANT SAFETY INFORMATION

Do not take UDENYCA® if you have had a serious allergic reaction to pegfilgrastim or filgrastim products.

What are possible side effects of UDENYCA®?
UDENYCA® may cause serious side effects, including:

  • Spleen rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency care right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious allergic reactions. UDENYCA® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using UDENYCA® and call your healthcare provider or get emergency medical help right away.
  • Sickle cell crises. You may have a serious sickle cell crisis if you have a sickle cell disorder and receive UDENYCA®. Serious sickle cell crises have happened in people with sickle cell disorders receiving pegfilgrastim that has sometimes led to death. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
  • Kidney injury (glomerulonephritis). UDENYCA® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
    • swelling of your face or ankles
    • blood in your urine or dark colored urine
    • you urinate less than usual
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with UDENYCA®.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with UDENYCA®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with UDENYCA®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. UDENYCA® can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • swelling or puffiness and are urinating less than usual
    • trouble breathing
    • swelling of your stomach-area (abdomen) and feeling of fullness
    • dizziness or feeling faint
    • a general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when UDENYCA® is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with UDENYCA®.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel that transports blood from the heart to the body) has been reported in patients who received pegfilgrastim. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.
  • Bone imaging (Nuclear Imaging): The formation of certain blood cells may increase and can be associated with short term changes in bone imaging. Your doctor should consider this whne interpreting bone imaging results.

The most common side effects of UDENYCA® are pain in the bones, arms, and legs. These are not all the possible side effects of UDENYCA®.

Call your healthcare provider for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or notify the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please read the Patient Information for UDENYCA®, and discuss it with your doctor. The physician Prescribing Information is also available.

back to top
back to top